严重肺挫伤早期肺泡灌洗液表面活性蛋白变化与肺功能及形态学改变的关系

目的探讨严重肺挫伤及缺血再灌注后早期肺泡灌洗液（BALF）中表面活性蛋白（SP）-A、B、C、D动态变化与肺功能及肺形态学改变的关系。方法75只兔随机分为对照组（A）、肺挫伤组（B）及缺血再灌注组（C）。每组均为25只。检测各组0，1，2，3，4h肺功能变化及BAIF中SP—A、B、C、D含量百分比，进行组织病理学及电镜检查。结果与A组比较，B、C组sSP—A、B、C、D含量百分比明显减少（P〈0．01）；肺功能出现明显的损害且呈持续下降（P〈0．05）；肺泡Ⅱ型细胞电镜及病理学检查呈不同程度的炎症及变性改变。结论严重肺挫伤BALF中SP—A、B、C、D动态变化与肺功能及肺组织病理学改变一致。     

可控性丝线留置术治疗体表难治性海绵状静脉畸形的实验及临床研究

目的研究可控性丝线的致栓效果及其治疗体表难治性海绵状静脉畸形的初步疗效。方法将丝线一端留置于不同管腔大小的静脉内,另一端挂于血管壁埋于皮下,实现其可控性,用经过不同处置的丝线,分别留置于兔耳缘静脉、股静脉,观察其引起血管栓塞的效果。选择致栓效果较好的丝线组,用于临床治疗难治性体表海绵状静脉畸形的患者。结果几种经不同处置的丝线,均能不同程度地起到闭塞血管的作用,对于管腔稍大,血流较快的静脉(兔股静脉),浸泡丝裂霉素并打结的丝线组,致栓效果最好;临床初步应用证实,可控性丝线治疗体表难治性静脉畸形,安全有效。结论可控性丝线静脉内留置术,是一种安全、有效、损伤小、操作简便的治疗体表难治性海绵状静脉畸形的新方法。     

抗氧化性维生素与男性生殖

生殖系统内过多的活性氧 (ROS)产生可导致精子膜脂质过氧化损伤 ,而抗氧化性维生素对于清除ROS 避免精子脂质过氧化损伤具有一定保护作用。本文就抗氧化性维生素在男性生殖中的作用及其在男性不育治疗等方面进行了综述     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.     

MR扩散加权成像鉴别脑结核瘤及高级星形细胞瘤和脑转移瘤的价值

目的探讨MR扩散加权成像（DWI）在脑结核瘤、高级星形细胞瘤和脑转移瘤鉴别诊断中的价值。方法14例脑结核瘤、15例脑高级星形细胞瘤和21例脑转移瘤患者，在术前或接受治疗前行常规MRI和DWI。测量并计算3种疾病瘤体、瘤周围水肿带的平均表观扩散系数（ADC）值和病灶与对侧相应部位正常脑白质区ADC值的比值（rADC值）。结果脑结核瘤瘤体平均ADC值和rADC值分别为（1．2±0．2）×10^-3mm^2·s^-1和1．6±0．3，高级星形细胞瘤瘤体平均ADC值和rADC值分别为（0．8±0．1）×10^-3mm^2·s^-1和1．1±0．1，转移瘤瘤体平均ADC值和rADC值分别为（0．8±0．1）×10^-3mm^2·s^-1和1．0±0．2。3种疾病瘤体平均ADC值（F=33．57，P〈0．01）之间和rADC值（F=33．27，P〈0．01）之间差异均有统计学意义。脑结核瘤瘤周水肿带平均ADC值和rADC值分别为（1．8±0．1）×10^-3mm^2·s^-1和2．5±0．2，脑高级星形细胞瘤瘤周水肿带平均ADC值和rADC值分别为（1．4±0．2）×10^-3mm^2·s^-1和1．8±0．3，脑转移瘤瘤周水肿带平均ADC值和rADC值分别为（1．9±0．2）×10^-3mm^2·s^-1和2．3±0．5。3种疾病瘤周围水肿带平均ADC值（F=23．17，P〈0．01）之间和rADC值（F=5．94，P〈0．01）之间差异均有统计学意义。结论结合MRI、DWI检测方法，根据病灶瘤体和瘤周水肿带的ADC和rADC值可帮助鉴别脑结核瘤、脑高级星形细胞瘤和脑转移瘤。     

婴幼儿血管瘤病理结构变化与临床演变过程的联系

目的探讨婴幼儿血管瘤患者临床演变过程和病理结构变化的内在联系。方法选取52例婴幼儿血管瘤标本,年龄2个月至11岁。采用HE染色观察各阶段血管瘤的病理特点,使用图像分析系统分析血管瘤组织中的细胞总数量、微血管总数量和总面积。结果按患儿出生后时间:1~6个月,血管瘤中细胞增殖速度快、排列紧密,微血管数量迅速增加;7~12个月,血管瘤中细胞数量迅速减少,微血管数量减少,但总面积继续扩大;1~3岁,大部分血管瘤组织呈微血管团样,微血管面积最大;3~5岁,微血管数量和总面积均迅速减少;5岁之后,大部分血管瘤消退完成,被纤维脂肪组织代替。结论婴幼儿血管瘤患者临床演变过程和病理结构变化有密切联系,病理结构变化主导临床演变过程。     

单丝聚丙烯合成非吸收齿状线在美容整形应用中并发症的防治及应用改进

目的探讨单丝聚丙烯合成非吸收齿状线在美容整形中的并发症产生的原因及应用方法及技术的改进。方法对近两年的单丝聚丙烯合成非吸收齿状线在美容整形中的应用进行总结与分析。结果改进应用方法后，并发症明显减少，效果加强。结论单丝聚丙烯合成非吸收齿状线在美容整形中应用得当，可减少并发症、取得显著效果。     

CD44v6和组织蛋白酶D表达与食管癌预后的关系

目的　研究CD4 4v6和组织蛋白酶D(cathepsinD ,CD)表达与食管癌生物学行为的关系。方法　应用免疫组化法 ,检测 6 5例食管鳞状细胞癌组织中CD4 4v6和CD表达水平。结果　在食管癌中CD4 4v6和CD表达阳性率分别为 5 8.5 %和 6 4 .6 %。CD4 4v6和CD表达均与肿瘤分级、浸润、淋巴结转移和预后相关。结论　CD4 4v6和CD异常表达与食管癌的病理生物学行为密切相关 ,可作为是预测食管癌转移潜能和评估食管癌预后的客观指标     

Perforation of the large bowel during colonoscopy in Singapore

The management of seven patients with colonoscopy-related perforations is described. This study demonstrates the need for an early laparotomy. A high index of suspicion is required to reach an early diagnosis. Patients with no preexisting medical problems who underwent early surgery recovered with little morbidity. In elderly patients (greater than 75 years), colonoscopic perforation can be fatal. Endoscopy should be performed with special care in such patients.     

Clinical Recurrences After Successful Accessory Pathway Ablation:

Dormant Accessory Pathways. Introduction : Recurrence of clinical symptoms after radiofrequency catheter ablation of an accessory atrioventricular pathway (AP) may be due to the late manifestation of an additional AP that was not detected during the initial ablation session. It was the purpose of this study to elucidate the phenomenon of these "dormant" APs.
Methods and Results : Of 1280 consecutive patients who underwent radiofrequency catheter ablation of an AP, 54 patients (4.2 %) developed clinical symptoms postablation, necessitating a repeat ablation session. Recurrence of conduction over the AP targeted al the initial ablation session was found in 45 patients, whereas in the other 9 patients (0.7%) the manifestation of a previously unnoticed AP had caused symptom recurrence. Retrospective analysis of the data from these patients' ablation sessions revealed that the late manifesting AP was ablated at a site clearly different from that of the initially targeted AP, and that the manifestation of conduction over a previously "dormant" AP occurred significantly later than the recovery of a presumably ablated AP. Seven (78%) of the 9 "dormant" APs were concealed, and none exhibited decremental conduction properties.
Conclusion : The incidence of clinical recurrences mediated by the late manifestation of conduction over a previously "dormant" AP is low. The lack of an anatomic vicinity of these predominantly concealed APs with the initially targeted AP and the lack of evidence for their presence during the initial ablation session suggest intermittent conduction as the most likely explanation for their late manifestation.